EPIGIST: An observational real-life study on patients with metastatic gastrointestinal stromal tumors receiving imatinib.

Date publication

janvier 2018

Journal

PloS one

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BOUCHE Olivier , Dr CHAIGNEAU Loïc , Dr RIOS Maria

Tous les auteurs :
Bouché O, Cesne AL, Rios M, Chaigneau L, Italiano A, Duffaud F, Lecomte T, Arsène D, Manfredi S, Aparicio T, Remy S, Isambert N, Collard O, Priou F, Bertucci F, Sambuc R, Bisot-Locard S, Bourges O, Chabaud S, Blay JY

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/30226855

Résumé

Gastrointestinal stromal tumors (GISTs) are rare, but represent the most common mesenchymal neoplasms of the gastrointestinal tract. EPIdemiology GIST, is an observational multicenter longitudinal follow-up cohort study reporting the prescribing patterns of imatinib in patients with GIST and the impact of the treatment in a real-world (standard clinical) setting.

Mots clés

Adult, Aged, Disease-Free Survival, Drug-Related Side Effects and Adverse Reactions, classification, Edema, chemically induced, Female, Follow-Up Studies, Gastrointestinal Stromal Tumors, complications, Humans, Imatinib Mesylate, administration & dosage, Male, Middle Aged, Mutation, Neoplasm Metastasis, Proto-Oncogene Proteins c-kit, genetics, Treatment Outcome

Référence

PLoS ONE. 2018 ;13(9):e0204117